These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29766245)

  • 1. [
    Rasul S; Hartenbach S; Rebhan K; Göllner A; Karanikas G; Mayerhoefer M; Mazal P; Hacker M; Hartenbach M
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2159-2169. PubMed ID: 29766245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medullary Thyroid Carcinoma: Do Ultrasonography and F-DOPA-PET-CT Influence the Initial Surgical Strategy?
    Brammen L; Niederle MB; Riss P; Scheuba C; Selberherr A; Karanikas G; Bodner G; Koperek O; Niederle B
    Ann Surg Oncol; 2018 Dec; 25(13):3919-3927. PubMed ID: 30306375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
    Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
    [No Abstract]   [Full Text] [Related]  

  • 4. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.
    Archier A; Heimburger C; Guerin C; Morange I; Palazzo FF; Henry JF; Schneegans O; Mundler O; Abdullah AE; Sebag F; Imperiale A; Taïeb D
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1027-33. PubMed ID: 26497699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of [18F]F-DOPA PET/CT in diagnostic and prognostic assessment of medullary thyroid cancer: a 15-year experience with 109 patients.
    Zhang Z; Yu J; Rainer E; Hargitai L; Jiang Z; Karanikas G; Traub-Weidinger T; Crevenna R; Hacker M; Li S
    Eur Thyroid J; 2024 Aug; 13(4):. PubMed ID: 38900599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The added diagnostic value of complementary gadoxetic acid-enhanced MRI to
    Puhr-Westerheide D; Cyran CC; Sargsyan-Bergmann J; Todica A; Gildehaus FJ; Kunz WG; Stahl R; Spitzweg C; Ricke J; Kazmierczak PM
    Cancer Imaging; 2019 Nov; 19(1):73. PubMed ID: 31727170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid.
    Caobelli F; Chiaravalloti A; Evangelista L; Saladini G; Schillaci O; Vadrucci M; Scalorbi F; Donner D; Alongi P;
    Ann Nucl Med; 2018 Jan; 32(1):7-15. PubMed ID: 28986764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of PET/CT with
    Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.
    Bodet-Milin C; Faivre-Chauvet A; Carlier T; Ansquer C; Rauscher A; Frampas E; Toulgoat F; Masson D; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
    J Nucl Med; 2021 Sep; 62(9):1221-1227. PubMed ID: 33547213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT.
    Asa S; Sonmezoglu K; Uslu-Besli L; Sahin OE; Karayel E; Pehlivanoglu H; Sager S; Kabasakal L; Ocak M; Sayman HB
    Ann Nucl Med; 2021 Aug; 35(8):900-915. PubMed ID: 33993425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
    Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels.
    Hoegerle S; Altehoefer C; Ghanem N; Brink I; Moser E; Nitzsche E
    Eur J Nucl Med; 2001 Jan; 28(1):64-71. PubMed ID: 11202454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study on the clinical relevance of
    Califano I; Pitoia F; Chirico R; De Salazar A; Bastianello MJ
    Endocrine; 2022 Jun; 77(1):143-150. PubMed ID: 35489000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values.
    Golubić AT; Pasini Nemir E; Žuvić M; Mutvar A; Kusačić Kuna S; Despot M; Samardžić T; Huić D
    Nucl Med Commun; 2017 Jul; 38(7):636-641. PubMed ID: 28562377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET.
    Sesti A; Mayerhoefer M; Weber M; Anner P; Wadsak W; Dudczak R; Haug A; Karanikas G
    Anticancer Res; 2014 Nov; 34(11):6647-54. PubMed ID: 25368270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioguided hepatic resection with
    López-Gómez J; Medina-Ornelas S; Salazar-Álvarez MA; Álvarez-Bojórquez M; Zaragoza-Cruz N; Melchor-Ruan J; Álvarez-Cano A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(4):244-249. PubMed ID: 29754940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of [
    Jamsek J; Hocevar M; Bergant D; Zaletel K; Rep S; Lezaic L
    Ann Nucl Med; 2021 Apr; 35(4):429-437. PubMed ID: 33544320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
    Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
    J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.
    Luster M; Karges W; Zeich K; Pauls S; Verburg FA; Dralle H; Glatting G; Buck AK; Solbach C; Neumaier B; Reske SN; Mottaghy FM
    Thyroid; 2010 May; 20(5):527-33. PubMed ID: 20450432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Accuracy of 18F-FDG PET/CT in Patients With Biochemical Evidence of Recurrent, Residual, or Metastatic Medullary Thyroid Carcinoma.
    Rodríguez-Bel L; Sabaté-Llobera A; Rossi-Seoane S; Reynés-Llompart G; Vercher Conejero JL; Cos-Domingo M; Moreno-Llorente P; Pérez-Maraver M; Cortés-Romera M; Gámez Cenzano C
    Clin Nucl Med; 2019 Mar; 44(3):194-200. PubMed ID: 30562193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.